Abstract

AstraZeneca PLC will report second-quarter 2026 results on July 27, 2026 Pre-MKt; this preview outlines consensus expectations for revenue, profitability, and EPS, and highlights product momentum and pipeline events that may steer the print and immediate stock reaction.

Market Forecast

Based on current-quarter forecasts, AstraZeneca PLC is expected to deliver revenue of 15.49 billion US dollars, implying year-over-year growth of 10.06%, with EBIT of 5.20 billion US dollars (+16.16% YoY) and adjusted EPS of 2.54 (+18.23% YoY). Forecast margins for gross profit and net profit are not specified, but prior-quarter profitability provides a high bar. Oncology remains the central revenue engine with continued uptake across lung and breast cancer therapies and additional label expansion catalysts; internal and partner-led assets are positioned to sustain mid-to-high-teens growth trends from the prior quarter. The most promising segment into this print is antibody-drug conjugates in Oncology, led by Enhertu, which generated 0.83 billion US dollars last quarter and grew 40.00% year over year, supported by broader approvals and increasing prescriber adoption.

Last Quarter Review

In the first quarter of 2026, AstraZeneca PLC posted revenue of 15.29 billion US dollars (+12.51% YoY), a gross profit margin of 82.52%, GAAP net profit attributable to shareholders of 3.08 billion US dollars for a 20.15% net profit margin, and adjusted EPS of 2.58 (+3.61% YoY). A key highlight was strong product execution in Oncology, where multiple therapies outperformed, complemented by double-digit expansion in Rare Disease and a solid contribution from Respiratory and Immunology. By business line, last quarter’s revenue mix comprised Oncology at 7.03 billion US dollars (noted +20% YoY), Cardiovascular, Renal and Metabolism at 3.05 billion US dollars (pressured by FX on a constant-currency basis), Rare Disease at 2.37 billion US dollars (+19% YoY), Respiratory and Immunology at 2.37 billion US dollars (+11% YoY), Vaccines and Immune Therapies at 0.44 billion US dollars, and Other at 0.24 billion US dollars.

Current Quarter Outlook

Oncology momentum and revenue durability

Oncology is set to remain the largest and fastest-growing revenue stream this quarter, following last quarter’s strong double-digit year-over-year growth and continued breadth across lung, breast, and hematology indications. Tagrisso remains foundational in first-line EGFR-mutant non-small cell lung cancer, with duration of therapy and geographic mix underpinning revenue resilience; the recent favorable outcome in a patent dispute reduces legal overhang and supports steady demand expectations. Imfinzi continues to capture share across lung and biliary tract settings, and its multi-indication expansion provides a diversified growth vector not solely centered on a single tumor type. Enhertu is the centerpiece of AstraZeneca’s antibody-drug conjugate franchise and continues to benefit from label expansion across HER2-positive and HER2-low settings, with the recent pan-tumor European clearance for HER2-positive solid tumors broadening the addressable population and reinforcing momentum into the quarter. The company’s push to expand its lung cancer franchise with a newly licensed EGFR exon20ins inhibitor adds another future growth layer, signaling management’s commitment to reinforcing the portfolio around mechanistic adjacencies in thoracic oncology. Taken together, breadth across mechanisms (TKI, PD-L1, ADC) and widening treatment settings suggest Oncology can again outperform group growth, with contributions skewed to therapies that have recently broadened indications. Operationally, higher-margin oncology therapies also tend to support group profitability, which could matter for the market’s reaction even if top-line results land in-line with expectations.

Rare Disease: steady volume growth with focus on sustainability

Rare Disease, driven by the Alexion unit, remains a dependable contributor, aided by continued patient growth in complement-mediated disorders and geographical expansion. Ultomiris continues to gain share as patients convert from older treatments, improving both net revenue and patient retention dynamics; last quarter’s 21% year-over-year growth sets a constructive baseline. The franchise’s mix is increasingly oriented to durable, chronic treatments with strong barriers to entry, enhancing visibility of cash flows and stabilizing quarterly run rates despite payer diligence. That said, the segment’s quarterly performance can be sensitive to timing of initiations and payer reviews, so investors will monitor whether conversion trends and new patient adds remain intact through the quarter. Pricing and access dynamics remain a watch item in major markets, but the limited competition in certain indications and ongoing geographic expansion provide tailwinds. For this print, modest sequential growth from Ultomiris and continued stability across the portfolio would support consolidated margin quality, given the high gross margins associated with this business.

Factors most likely to move the stock this quarter

Three cross-currents stand out for this quarter’s share-price reaction: the cadence of Oncology growth, pipeline readouts and associated headline risk, and incremental clarity on margins. Oncology growth remains the core narrative; investors will look for confirmation that double-digit expansion persists and that recently expanded indications translate into further uptake for Imfinzi and Enhertu. Pipeline events can quickly influence sentiment: a recent late-stage miss in a partnered neurology program triggered a short-lived drawdown, showing the stock’s sensitivity to negative readouts even when revenue impact is small; conversely, portfolio-enriching deals and regulatory wins (such as the broad EU label for Enhertu and the EGFR exon20ins deal) can strengthen the outlook. On profitability, the prior quarter’s 82.52% gross margin and 20.15% net margin set a high-quality baseline; any indication of mix benefits from premium oncology therapies, or disciplined operating spend as launches scale, could be read positively. Currency remains a familiar variable for the company given its geographic mix, so commentary on constant-currency growth versus reported growth will matter for interpreting the guidance trajectory. Product-level color will also be scrutinized: stabilization in Cardiovascular, Renal and Metabolism following FX headwinds last quarter would be taken as a sign of resilience, while continued acceleration in Respiratory and Immunology would reinforce the company’s balanced growth profile. Finally, any early signals on the commercial rollout pace for newly broadened oncology indications, or incremental updates on near-term regulatory milestones, may sway post-earnings performance even if top-line and EPS land near consensus.

Analyst Opinions

Across published views in the past six months, the balance of opinion is bullish, with eight Buy ratings versus one Sell, yielding an 8:1 bullish-to-bearish ratio; there is also one Hold view in the period. High-profile institutions on the bullish side include Goldman Sachs, Citi, J.P. Morgan, Berenberg, Jefferies, Bernstein, and Guggenheim, which have reiterated or initiated positive stances with constructive price targets. The common threads behind these bullish positions are the durability of Oncology growth led by Tagrisso, Imfinzi, and Enhertu, the expanding contribution from Rare Disease, and continued advancement of a broad late-stage pipeline. Analysts also point to the earnings algorithm implied by the current-quarter forecasts: revenue growth expected around 10.06% year over year with operating leverage reflected in projected EBIT growth of 16.16% and adjusted EPS growth of 18.23%. Several bullish notes emphasize that the broadening ADC footprint and recent pan-tumor momentum for Enhertu can sustain a premium growth profile versus peers, while the recent lung cancer licensing move enhances long-term competitive positioning in thoracic oncology. From a risk-balancing standpoint, bullish research acknowledges occasional trial volatility but argues that the product diversity across mechanisms and indications helps absorb setbacks that have limited near-term revenue implications. On valuation, supportive views often cite a path to consistent double-digit EPS expansion, driven by oncology mix, continued Rare Disease growth, and operating discipline as launches progress. In summary, the majority view anticipates that second-quarter delivery aligned with the revenue and EPS growth framework, plus evidence of further oncology uptake and clear margin commentary, would justify maintaining a constructive stance into the event.